REBEC

Go to main content [1]
Go to main menu [2]
Enable hight contrast [3]

-

-

-

-

-

✅ VALIDAR RBR/CHECK REGISTER CODE 📊 PAINEL DE DADOS/DASHBOARD

Public trial

Sensitivity after composite resin restorations with previous desensitizing application

Date of registration: 03/16/2020 ^(mm/dd/yyyy)
Last approval date : 03/16/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Medical Record Model Oriented to problems with the use of medications in patients with Heart Failure admitted to the Intensive Care Unit

Date of registration: 03/13/2020 ^(mm/dd/yyyy)
Last approval date : 03/13/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Traditional resistance training and use of blood flow restriction in muscle hypertrophy and functionality gains

Date of registration: 03/13/2020 ^(mm/dd/yyyy)
Last approval date : 03/13/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of Self Massage on muscle strength in female soccer athletes

Date of registration: 03/12/2020 ^(mm/dd/yyyy)
Last approval date : 03/12/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Study of quality of life after Sialendoscopy

Date of registration: 03/11/2020 ^(mm/dd/yyyy)
Last approval date : 03/12/2020 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Observational

Postoperative follow-up of 5 years of surgical treatment for urinary loss of effort

Date of registration: 03/11/2020 ^(mm/dd/yyyy)
Last approval date : 03/11/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Effects of crustacean oil supplementation on lipid profile and inflammatory markers in overweight women

Date of registration: 03/11/2020 ^(mm/dd/yyyy)
Last approval date : 03/11/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The influence of genetic variations on Migraine

Date of registration: 03/11/2020 ^(mm/dd/yyyy)
Last approval date : 03/11/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

TheraTogs garments on trunk balance in child with Cerebral Palsy

Date of registration: 03/11/2020 ^(mm/dd/yyyy)
Last approval date : 03/11/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Impact of diode laser in treatment of oral white lesions and proetins in the saliva related to recurrence and malignant transformation

Date of registration: 03/11/2020 ^(mm/dd/yyyy)
Last approval date : 03/11/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of a muscle strengthening of the 1st dorsal interosseous in subjects with rhizarthrosis: a randomized controlled trial.

Date of registration: 03/11/2020 ^(mm/dd/yyyy)
Last approval date : 03/11/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Management of Gingival Smile using Botulinum Toxin

Date of registration: 03/11/2020 ^(mm/dd/yyyy)
Last approval date : 03/11/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of Grape Seed Flour consumption on intestinal flora and metabolic parameters of individuals with Obesity

Date of registration: 03/11/2020 ^(mm/dd/yyyy)
Last approval date : 03/11/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Early pulmonary rehabilitation with elastic bands in patients with Exacerbated Chronic Obstructive Pulmonary Disease: Focus on cardiovascular health - vascular function

Date of registration: 03/11/2020 ^(mm/dd/yyyy)
Last approval date : 03/11/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of factors that worsen survival in metastatic patients of skin carcinoma

Date of registration: 03/11/2020 ^(mm/dd/yyyy)
Last approval date : 03/11/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

How dance can improve the way of walking normally and walking while talking in the elderly

Date of registration: 03/11/2020 ^(mm/dd/yyyy)
Last approval date : 03/11/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Clinical and microbiological evaluation after treatment at the site of chronic periodontal disease, with gels containing antimicrobial agents

Date of registration: 03/10/2020 ^(mm/dd/yyyy)
Last approval date : 03/10/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Power resistance training versus traditional on muscle adaptations and functionality in elderly woman

Date of registration: 03/10/2020 ^(mm/dd/yyyy)
Last approval date : 03/10/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of whole body vibration on urine loss, quality of life and functioning of women with loss of urine: a double-blind randomized clinical trials

Date of registration: 03/10/2020 ^(mm/dd/yyyy)
Last approval date : 03/10/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Postoperative pain in patients after root canals treatment using 8.25% sodium hypochlorite as irrigating solution

Date of registration: 03/10/2020 ^(mm/dd/yyyy)
Last approval date : 03/10/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

04/02/2026

Opinion: New Legal Framework for Clinical Research Could Inject Billions into Brazil

04/01/2026 | Fábio Franke | Exame

https://exame.com/bussola/novo-marco-legal-da-pesquisa-clinica-pode-injetar-bilhoes-no-brasil/?utm_source=copiaecola&utm_medium=compartilhamento

Understand how the new regulation corrects historical distortions and positions the country as a strategic hub for global protocols.

The vaccine that prevented millions of deaths in the pandemic. The most modern cancer treatments that increased survival rates in cases previously considered incurable.

And even advances in regenerative therapies with the use of polyamine in spinal cord injuries that challenge limits previously considered impossible. None of this would be possible without clinical research.

The urgency of access and the time factor

For those facing a complex diagnosis, especially an oncological one, the clock doesn't run in years, it runs in decisions. In access. In opportunity. Before reaching the doctor's office, every advance that today seems "normal" had to begin as a hypothesis, go through years of testing, and, above all, gain time. Time for study, approval, and access.

It is under this urgency that Law No. 14,874/2024, the new legal framework for clinical research in Brazil, should be understood.

Economic Impact and New Investments

The approval of the law represents more than a regulatory advance. It corrects a historical distortion: the slowness that isolated Brazilian science from the rest of the world.

Today, the country accounts for less than 2% of global clinical research, a clear mismatch between capacity and participation. The expectation is that Brazil will attract approximately R$ 3 billion annually in direct investments and up to R$ 5 billion…

04/01/2026

The Indo-Australian Biotech Bridge: Strategic Synergies in Clinical Trials

04/01/2026 | The Policy Edge

https://www.policyedge.in/p/the-indo-australian-biotech-bridge-strategic-synergies-in-clinical-trials

The Australian Trade and Investment Commission (Austrade) has highlighted a burgeoning strategic partnership at BioAsia 2026, driven by India’s AUD 236 billion biotech sector seeking Australia’s regulatory speed.

Indian innovators are increasingly utilising Australia’s Clinical Trial Notification (CTN) pathway, which allows trials to commence immediately after ethics approval, often within 6 to 12 weeks, compared to traditional 16-week timelines elsewhere. This "Fast-Track" access is coupled with a high degree of Data Governance; Australian Phase 1 data is widely accepted by the US FDA and European EMA.

While Australia provides rapid, high-quality early-phase data and significant R&D tax benefits, India offers the late-phase scale, massive patient populations, and cost-effective manufacturing necessary for global commercialisation.

Strategic Components of the Biotech Corridor

Regulatory Efficiency: Australia’s risk-based CTN system offers a competitive advantage for firms racing for "first-in-human" or "proof-of-concept" data.
Global Market Entry: Australian trial results act as a validated gateway for Indian firms targeting high-value markets in Boston, Paris, and beyond.
Complementary Strengths: The partnership creates a "Practical Pathway" where Australia handles early-phase precision and India manages development volume and mass production.
Manufacturing Synergy: Australian biotech firms are simultaneously looking to India to leverage its immense manufacturing capacity to bring Australian discoveries to the global market.

04/01/2026

IAVI announces the onset of first-in-human Phase 1 clinical trial of broadly neutralizing antibodies (bnAbs) to prevent HIV transmission

04/01/2026 | IAVI ( International AIDS Vaccine Initiative)

https://www.iavi.org/features/iavi-announces-first-in-humans-clinical-trial-of-hiv-antibodies/

The trial, run by the HIV Vaccines Trial Network (HVTN) and HIV Prevention Trials Network (HPTN), will evaluate the safety, dosing, pharmacokinetics, and ability of four bnAbs to neutralize HIV

IAVI is pleased to announce the use of its broadly neutralizing antibody (bnAb), ePGT121v1-LS, in a first-in-human, Phase 1 clinical trial that began on March 19, 2026. IAVI’s HIV bnAbs program is designed to develop efficacious antibodies that can prevent HIV transmission. The program is specifically geared for eventual use to prevent HIV transmission to infants during the post-natal period. With 120,000 children newly acquiring HIV in 2024 alone, and 50 percent of infant HIV acquisition taking place in the breastfeeding period, there is a clear need for additional prevention tools developed to protect this vulnerable population. The onset of this clinical trial is a significant step in examining whether a combination of broadly neutralizing antibodies could be this new tool. With robust safety and dose data collected through this study, which has only adult participants, IAVI’s team will have the necessary data to plan future studies in infants.

This clinical trial, HVTN 141/HPTN105, will use four antibodies that target different HIV receptors. Based on past studies, the antibodies together are expected to neutralize more strains of HIV than any antibody alone. IAVI’s antibody will be given by itself and together with two of the three additional antibodies, VRC07-523LS and PGDM1400LS. The fourth antibody, PGT121.414.LS, will be given by itself and in combination with these same two antibodies. Doses will be delivered by IV, under…

03/31/2026

Brazilian study shows improved memory in Alzheimer's patients treated with cannabis

03/30/2026 | Raphael Bezerra | Jornal Opção

https://www.jornalopcao.com.br/ultimas-noticias/estudo-brasileiro-aponta-melhora-na-memoria-em-pacientes-com-alzheimer-tratados-com-cannabis-808878/

A group of 13 Brazilian researchers led by Francisney Pinto Nascimento, PhD in pharmacology at the Federal University of Latin American Integration (Unila), identified cognitive improvement in Alzheimer’s patients treated with low-dose cannabis extracts. The results appear in two scientific publications—a 2022 report and a randomized clinical trial published in 2025—which point to positive effects on memory, with a safety profile considered favorable.

The research line investigates the use of cannabinoids as a therapeutic alternative for improving Alzheimer’s, a neurodegenerative condition that affects millions of people worldwide and for which there is still no cure. For biomedical scientist and researcher Isabela Carvalho Freitas, affiliated with the Federal University of Goiás (UFG), the observed effects can be explained by the interaction of cannabinoids with the endocannabinoid system, which is responsible for regulating functions such as mood, sleep, appetite, and stress response.

According to the expert, modulating this system may contribute to symptom management and improved quality of life in Alzheimer’s patients, particularly regarding behavioral symptoms, which still pose significant clinical challenges.

She also highlights the growing academic interest in the topic and notes that historical regulatory barriers have hindered the production of robust scientific evidence. “The lack of research restricts use, and the restriction hinders the advancement of research,” she states in an interview with Jornal…

03/31/2026

The Right to Health: Between Innovation and Regulation of Polylaminin

03/30/2026 | Maria Prevot and Franco Mauro Russo Brugioni | Migalhas.com

https://www.migalhas.com.br/depeso/452905/o-direito-a-saude-entre-a-inovacao-e-a-regulacao-da-polilaminina

Polylaminin, in initial trials, sparks legal debate over coverage of experimental treatments in the face of urgency and scientific uncertainty.

Reports have recently surfaced regarding a new substance, still in the testing phase, that could be used in an attempt to reverse paralysis resulting from spinal cord injury.

This substance is polylaminin, a derivative of laminin, developed through research at the Federal University of Rio de Janeiro (UFRJ) and currently funded for clinical trials. The development of this substance brings a topic in Health Law back to the center of the debate: when therapeutic hope gives rise to legal obligations for coverage before scientific consolidation. The case is emblematic because the news highlights that this is investigational technology, in the early stages of human testing, aimed at severe acute spinal cord injuries.

From a regulatory standpoint, the turning point is the transition from the experimental phase to authorized clinical research. In January 2026, Anvisa authorized a Phase 1 study to evaluate the safety of polylaminin in five patients with complete thoracic injuries. The Ministry of Health has signaled institutional interest in innovative technologies for the SUS. These developments do not imply automatic registration or incorporation, but they raise the level of seriousness of the treatment in the eyes of the judiciary, as they indicate risk management and monitoring of adverse events.

In this interim period—between research authorization and incorporation—the likelihood of judicial rulings increases. There is a concrete…